TÜBINGEN, Germany / BOSTON, MA, USA – July 12, 2019

CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan Menichella, Chief Executive Officer, and Dimitris Voliotis, Chief Development Officer, will participate in two panels at the ROTH RNA Revolution Conference in New York on Wednesday, July 17, 2019. The Company will also host one-on-one meetings.